- Info
- Insider Trading
- Financials
- Holders: XFOR, XFOR
X4 Pharmaceuticals, Inc - Common Stock (XFOR)
CUSIP: 98420X202
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 87,101,353
- Total 13F shares
- 83,045
- Share change
- +83,045
- Total reported value
- $20,007
- Price per share
- $0.24
- Number of holders
- 2
- Value change
- +$20,007
- Number of buys
- 2
Quarterly Holders Quick Answers
What is CUSIP 98420X202?
CUSIP 98420X202 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q2 2025
Recent filing periods for CUSIP 98420X202:
Top shareholders of XFOR - X4 Pharmaceuticals, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
213%
|
16,915,784
|
$12,409,419 | — | 31 Dec 2024 | |
| NEA Management Company, LLC |
13F
|
Company |
189%
|
14,986,793
|
$10,994,311 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
139%
|
11,060,645
|
$8,114,089 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.8%
from 13D/G
|
8,200,903
|
$6,019,463 | — | 31 Dec 2024 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
92%
|
7,310,650
|
$5,363,093 | — | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
90%
|
7,133,515
|
$5,233,147 | — | 31 Dec 2024 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
62%
|
4,937,000
|
$3,621,783 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
44%
|
3,497,212
|
$2,565,869 | — | 31 Dec 2024 | |
| AXA S.A. |
13F
|
Company |
39%
|
3,072,143
|
$2,253,724 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
39%
|
3,057,297
|
$2,242,833 | — | 31 Dec 2024 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
32%
|
2,546,458
|
$1,868,082 | — | 31 Dec 2024 | |
| Paula Ragan |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
4,526,964
mixed-class rows
|
$1,515,173 | — | 12 Feb 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
24%
|
1,887,611
|
$1,384,751 | — | 31 Dec 2024 | |
| Pale Fire Capital SE |
13F
|
Company |
18%
|
1,401,964
|
$1,028,481 | — | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
18%
|
1,392,826
|
$1,021,776 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
17%
|
1,357,539
|
$995,891 | — | 31 Dec 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
16%
|
1,273,635
|
$934,000 | — | 31 Dec 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
16%
|
1,264,358
|
$928,039 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
12%
|
923,060
|
$677,526 | — | 31 Dec 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
10%
|
797,411
|
$584,981 | — | 31 Dec 2024 | |
| Mary DiBiase |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
1,569,228
mixed-class rows
|
$518,005 | — | 12 Feb 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
8.2%
|
650,000
|
$476,840 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
7.4%
|
583,483
|
$428,043 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
6.9%
|
550,495
|
$403,844 | — | 31 Dec 2024 | |
| Christophe Arbet-Engels |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
1,045,023
mixed-class rows
|
$392,350 | — | 12 Feb 2025 | |
| Adam S. Mostafa |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
1,373,414
mixed-class rows
|
$385,900 | — | 12 Feb 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
6%
|
477,638
|
$350,395 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
5.8%
|
459,653
|
$337,202 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
5.5%
|
438,208
|
$321,469 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
4.3%
|
344,747
|
$252,906 | — | 31 Dec 2024 | |
| Arthur Taveras |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
816,274
mixed-class rows
|
$218,459 | — | 04 Oct 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
3.4%
|
267,628
|
$195,369 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
3.4%
|
266,157
|
$195,253 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.3%
|
258,759
|
$189,826 | — | 31 Dec 2024 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
2.4%
|
191,904
|
$140,000 | — | 31 Dec 2024 | |
| SG Americas Securities, LLC |
13F
|
Company |
2.3%
|
183,152
|
$134,000 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
2.3%
|
178,725
|
$131,174 | — | 31 Dec 2024 | |
| Derek M. Meisner |
3/4/5
|
Chief Legal Officer |
—
class O/S missing
|
145,155
|
$130,640 | — | 17 Aug 2022 | |
| David M. Knott Jr. |
13F
|
Individual |
1.9%
|
154,071
|
$113,026 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
1.7%
|
137,207
|
$100,655 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.7%
|
133,502
|
$97,857 | — | 31 Dec 2024 | |
| Diego Cadavid |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
104,107
|
$93,696 | — | 01 Mar 2022 | |
| Alison Frances Lawton |
3/4/5
|
Director |
—
class O/S missing
|
96,667
|
$85,241 | — | 10 Jun 2024 | |
| William Aliski |
3/4/5
|
Director |
—
class O/S missing
|
96,667
|
$85,241 | — | 10 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.4%
|
109,570
|
$80,381 | — | 31 Dec 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
1.2%
|
96,397
|
$70,717 | — | 31 Dec 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
1.1%
|
83,544
|
$61,288 | — | 31 Dec 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.99%
|
78,518
|
$57,601 | — | 31 Dec 2024 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.95%
|
75,607
|
$55,466 | — | 31 Dec 2024 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.94%
|
75,000
|
$55,020 | — | 31 Dec 2024 |
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) as of Q1 2025
As of 31 Mar 2025,
X4 Pharmaceuticals, Inc - Common Stock (XFOR) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
83,045 shares.
The largest 2 holders included
PRICE T ROWE ASSOCIATES INC /MD/ and EverSource Wealth Advisors, LLC.
This page lists
2
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2025 Across Filers
Q4 2025 holders
75
Q1 2025 holders
2
Holder diff
-73
| Investor | Q4 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.